In Vitro Evaluations of Topical Agents to Treat Acanthamoeba Keratitis

Purpose To evaluate the effectiveness of topical agents for the treatment of Acanthamoeba keratitis (AK). Design Laboratory research. Participants Fifty-six Acanthamoeba isolates from 56 patients with clinically proven AK were studied. Methods The effectiveness of 7 agents against Acanthamoeba cysts...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Ophthalmology (Rochester, Minn.) Minn.), 2014-10, Vol.121 (10), p.2059-2065
Hauptverfasser: Sunada, Atsuko, MT, Kimura, Keigo, MT, Nishi, Isao, MT, PhD, Toyokawa, Masahiro, MT, PhD, Ueda, Akiko, MT, Sakata, Tomomi, MT, Suzuki, Takashi, MD, PhD, Inoue, Yoshitsugu, MD, PhD, Ohashi, Yuichi, MD, PhD, Asari, Seishi, MT, PhD, Iwatani, Yoshinori, MD, PhD
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 2065
container_issue 10
container_start_page 2059
container_title Ophthalmology (Rochester, Minn.)
container_volume 121
creator Sunada, Atsuko, MT
Kimura, Keigo, MT
Nishi, Isao, MT, PhD
Toyokawa, Masahiro, MT, PhD
Ueda, Akiko, MT
Sakata, Tomomi, MT
Suzuki, Takashi, MD, PhD
Inoue, Yoshitsugu, MD, PhD
Ohashi, Yuichi, MD, PhD
Asari, Seishi, MT, PhD
Iwatani, Yoshinori, MD, PhD
description Purpose To evaluate the effectiveness of topical agents for the treatment of Acanthamoeba keratitis (AK). Design Laboratory research. Participants Fifty-six Acanthamoeba isolates from 56 patients with clinically proven AK were studied. Methods The effectiveness of 7 agents against Acanthamoeba cysts was determined in vitro. The agents were 1.0% povidone-iodine, 0.05% benzalkonium chloride (BZC), 0.02% chlorhexidine gluconate (CHG), 0.1% propamidine isethionate, 0.02% polyhexamethylene biguanide (PHMB), 5.0% natamycin, and 1.0% voriconazole (VRCZ). These concentrations are those recommended for patients. In addition, 10-fold dilutions of each of the agents were tested. After exposing the cysts to each agent at 35°C for 1 hour or 24 hours, the agents were removed by centrifugal washing. The exposed cysts were observed by optical microscopy for 7 days. In addition, the fine structures of the exposed isolates were examined by transmission electron microscopy (TEM). The genotype of the isolates was determined by 18S rDNA fragment sequencing. Main Outcome Measures The in vitro susceptibility was determined by complete growth inhibition, and the morphologic appearance was determined by TEM. The genotypes of the 56 isolates were determined by 18S rDNA fragment sequencing. Results The Acanthamoeba cysts were most susceptible to natamycin, followed by povidone-iodine, BZC, PHMB, propamidine, and CHG. None of the strains was susceptible to VRCZ. The susceptibilities to PHMB and CHG may be time dependent and to propamidine may be concentration dependent. Transmission electron microscopy showed changes in the inner structure of the cysts exposed to natamycin and povidone-iodine. The Acanthamoeba genotype was T4 in 52 isolates, and cysts with the same genotype had different agent susceptibilities. Conclusions Natamycin and povidone-iodine had excellent cysti-static (or cystcidal) effects, and PHMB and propamidine did not. There was no correlation between agent effectiveness and Acanthamoeba genotype. Therefore, susceptibility tests of isolates are needed to choose the most appropriate agent, and our results can be a guideline for choosing the most appropriate agent for immediate empirical treatment of AK.
doi_str_mv 10.1016/j.ophtha.2014.04.013
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1566112505</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0161642014003601</els_id><sourcerecordid>1566112505</sourcerecordid><originalsourceid>FETCH-LOGICAL-c553t-d736133e4820dcd2c4b051ed54e765a50e80c336fb629a78731e72e3dfc61a0a3</originalsourceid><addsrcrecordid>eNqFkU2OEzEQhS0EYjKBGyDUSzYdqvzXnQ1SNJo_MRILAlvLcVczDp12sN0jzW04CyfDrQws2CCVVJtX71V9xdgbhBUC6vf7VTje53u74oByBaVQPGMLVHJdywbFc7YoMqy15HDGzlPaA4DWQr5kZ1y2LaxBLdj17fjr51efY6guH-ww2ezDmKrQV9tw9M4O1eYbjTlVOVTbSDZXG2fHEnsItLPVR4plIvv0ir3o7ZDo9VNfsi9Xl9uLm_ru0_XtxeaudkqJXHeN0CgEyZZD5zru5A4UUqckNVpZBdSCE0L3O83XtmkbgdRwEl3vNFqwYsnenXyPMfyYKGVz8MnRMNiRwpQMKq0RuQJVpPIkdTGkFKk3x-gPNj4aBDMjNHtzQmhmhAZKld2W7O1TwrQ7UPd36A-zIvhwElC588FTNMl5Gh11PpLLpgv-fwn_GrjBjzPs7_RIaR-mOBaGBk3iBszn-Y3zF1ECCF0cfgNJCph8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1566112505</pqid></control><display><type>article</type><title>In Vitro Evaluations of Topical Agents to Treat Acanthamoeba Keratitis</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Sunada, Atsuko, MT ; Kimura, Keigo, MT ; Nishi, Isao, MT, PhD ; Toyokawa, Masahiro, MT, PhD ; Ueda, Akiko, MT ; Sakata, Tomomi, MT ; Suzuki, Takashi, MD, PhD ; Inoue, Yoshitsugu, MD, PhD ; Ohashi, Yuichi, MD, PhD ; Asari, Seishi, MT, PhD ; Iwatani, Yoshinori, MD, PhD</creator><creatorcontrib>Sunada, Atsuko, MT ; Kimura, Keigo, MT ; Nishi, Isao, MT, PhD ; Toyokawa, Masahiro, MT, PhD ; Ueda, Akiko, MT ; Sakata, Tomomi, MT ; Suzuki, Takashi, MD, PhD ; Inoue, Yoshitsugu, MD, PhD ; Ohashi, Yuichi, MD, PhD ; Asari, Seishi, MT, PhD ; Iwatani, Yoshinori, MD, PhD</creatorcontrib><description>Purpose To evaluate the effectiveness of topical agents for the treatment of Acanthamoeba keratitis (AK). Design Laboratory research. Participants Fifty-six Acanthamoeba isolates from 56 patients with clinically proven AK were studied. Methods The effectiveness of 7 agents against Acanthamoeba cysts was determined in vitro. The agents were 1.0% povidone-iodine, 0.05% benzalkonium chloride (BZC), 0.02% chlorhexidine gluconate (CHG), 0.1% propamidine isethionate, 0.02% polyhexamethylene biguanide (PHMB), 5.0% natamycin, and 1.0% voriconazole (VRCZ). These concentrations are those recommended for patients. In addition, 10-fold dilutions of each of the agents were tested. After exposing the cysts to each agent at 35°C for 1 hour or 24 hours, the agents were removed by centrifugal washing. The exposed cysts were observed by optical microscopy for 7 days. In addition, the fine structures of the exposed isolates were examined by transmission electron microscopy (TEM). The genotype of the isolates was determined by 18S rDNA fragment sequencing. Main Outcome Measures The in vitro susceptibility was determined by complete growth inhibition, and the morphologic appearance was determined by TEM. The genotypes of the 56 isolates were determined by 18S rDNA fragment sequencing. Results The Acanthamoeba cysts were most susceptible to natamycin, followed by povidone-iodine, BZC, PHMB, propamidine, and CHG. None of the strains was susceptible to VRCZ. The susceptibilities to PHMB and CHG may be time dependent and to propamidine may be concentration dependent. Transmission electron microscopy showed changes in the inner structure of the cysts exposed to natamycin and povidone-iodine. The Acanthamoeba genotype was T4 in 52 isolates, and cysts with the same genotype had different agent susceptibilities. Conclusions Natamycin and povidone-iodine had excellent cysti-static (or cystcidal) effects, and PHMB and propamidine did not. There was no correlation between agent effectiveness and Acanthamoeba genotype. Therefore, susceptibility tests of isolates are needed to choose the most appropriate agent, and our results can be a guideline for choosing the most appropriate agent for immediate empirical treatment of AK.</description><identifier>ISSN: 0161-6420</identifier><identifier>EISSN: 1549-4713</identifier><identifier>DOI: 10.1016/j.ophtha.2014.04.013</identifier><identifier>PMID: 24880905</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Acanthamoeba - drug effects ; Acanthamoeba - genetics ; Acanthamoeba - isolation &amp; purification ; Acanthamoeba Keratitis - drug therapy ; Acanthamoeba Keratitis - parasitology ; Anti-Infective Agents, Local - pharmacology ; Antiprotozoal Agents - pharmacology ; Disinfectants - pharmacology ; DNA, Protozoan - analysis ; Genotype ; Humans ; Ophthalmic Solutions - pharmacology ; Ophthalmology ; RNA, Ribosomal, 18S - genetics</subject><ispartof>Ophthalmology (Rochester, Minn.), 2014-10, Vol.121 (10), p.2059-2065</ispartof><rights>American Academy of Ophthalmology</rights><rights>2014 American Academy of Ophthalmology</rights><rights>Copyright © 2014 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c553t-d736133e4820dcd2c4b051ed54e765a50e80c336fb629a78731e72e3dfc61a0a3</citedby><cites>FETCH-LOGICAL-c553t-d736133e4820dcd2c4b051ed54e765a50e80c336fb629a78731e72e3dfc61a0a3</cites><orcidid>0000-0002-1005-9634</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ophtha.2014.04.013$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>315,781,785,3551,27928,27929,45999</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24880905$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sunada, Atsuko, MT</creatorcontrib><creatorcontrib>Kimura, Keigo, MT</creatorcontrib><creatorcontrib>Nishi, Isao, MT, PhD</creatorcontrib><creatorcontrib>Toyokawa, Masahiro, MT, PhD</creatorcontrib><creatorcontrib>Ueda, Akiko, MT</creatorcontrib><creatorcontrib>Sakata, Tomomi, MT</creatorcontrib><creatorcontrib>Suzuki, Takashi, MD, PhD</creatorcontrib><creatorcontrib>Inoue, Yoshitsugu, MD, PhD</creatorcontrib><creatorcontrib>Ohashi, Yuichi, MD, PhD</creatorcontrib><creatorcontrib>Asari, Seishi, MT, PhD</creatorcontrib><creatorcontrib>Iwatani, Yoshinori, MD, PhD</creatorcontrib><title>In Vitro Evaluations of Topical Agents to Treat Acanthamoeba Keratitis</title><title>Ophthalmology (Rochester, Minn.)</title><addtitle>Ophthalmology</addtitle><description>Purpose To evaluate the effectiveness of topical agents for the treatment of Acanthamoeba keratitis (AK). Design Laboratory research. Participants Fifty-six Acanthamoeba isolates from 56 patients with clinically proven AK were studied. Methods The effectiveness of 7 agents against Acanthamoeba cysts was determined in vitro. The agents were 1.0% povidone-iodine, 0.05% benzalkonium chloride (BZC), 0.02% chlorhexidine gluconate (CHG), 0.1% propamidine isethionate, 0.02% polyhexamethylene biguanide (PHMB), 5.0% natamycin, and 1.0% voriconazole (VRCZ). These concentrations are those recommended for patients. In addition, 10-fold dilutions of each of the agents were tested. After exposing the cysts to each agent at 35°C for 1 hour or 24 hours, the agents were removed by centrifugal washing. The exposed cysts were observed by optical microscopy for 7 days. In addition, the fine structures of the exposed isolates were examined by transmission electron microscopy (TEM). The genotype of the isolates was determined by 18S rDNA fragment sequencing. Main Outcome Measures The in vitro susceptibility was determined by complete growth inhibition, and the morphologic appearance was determined by TEM. The genotypes of the 56 isolates were determined by 18S rDNA fragment sequencing. Results The Acanthamoeba cysts were most susceptible to natamycin, followed by povidone-iodine, BZC, PHMB, propamidine, and CHG. None of the strains was susceptible to VRCZ. The susceptibilities to PHMB and CHG may be time dependent and to propamidine may be concentration dependent. Transmission electron microscopy showed changes in the inner structure of the cysts exposed to natamycin and povidone-iodine. The Acanthamoeba genotype was T4 in 52 isolates, and cysts with the same genotype had different agent susceptibilities. Conclusions Natamycin and povidone-iodine had excellent cysti-static (or cystcidal) effects, and PHMB and propamidine did not. There was no correlation between agent effectiveness and Acanthamoeba genotype. Therefore, susceptibility tests of isolates are needed to choose the most appropriate agent, and our results can be a guideline for choosing the most appropriate agent for immediate empirical treatment of AK.</description><subject>Acanthamoeba - drug effects</subject><subject>Acanthamoeba - genetics</subject><subject>Acanthamoeba - isolation &amp; purification</subject><subject>Acanthamoeba Keratitis - drug therapy</subject><subject>Acanthamoeba Keratitis - parasitology</subject><subject>Anti-Infective Agents, Local - pharmacology</subject><subject>Antiprotozoal Agents - pharmacology</subject><subject>Disinfectants - pharmacology</subject><subject>DNA, Protozoan - analysis</subject><subject>Genotype</subject><subject>Humans</subject><subject>Ophthalmic Solutions - pharmacology</subject><subject>Ophthalmology</subject><subject>RNA, Ribosomal, 18S - genetics</subject><issn>0161-6420</issn><issn>1549-4713</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU2OEzEQhS0EYjKBGyDUSzYdqvzXnQ1SNJo_MRILAlvLcVczDp12sN0jzW04CyfDrQws2CCVVJtX71V9xdgbhBUC6vf7VTje53u74oByBaVQPGMLVHJdywbFc7YoMqy15HDGzlPaA4DWQr5kZ1y2LaxBLdj17fjr51efY6guH-ww2ezDmKrQV9tw9M4O1eYbjTlVOVTbSDZXG2fHEnsItLPVR4plIvv0ir3o7ZDo9VNfsi9Xl9uLm_ru0_XtxeaudkqJXHeN0CgEyZZD5zru5A4UUqckNVpZBdSCE0L3O83XtmkbgdRwEl3vNFqwYsnenXyPMfyYKGVz8MnRMNiRwpQMKq0RuQJVpPIkdTGkFKk3x-gPNj4aBDMjNHtzQmhmhAZKld2W7O1TwrQ7UPd36A-zIvhwElC588FTNMl5Gh11PpLLpgv-fwn_GrjBjzPs7_RIaR-mOBaGBk3iBszn-Y3zF1ECCF0cfgNJCph8</recordid><startdate>20141001</startdate><enddate>20141001</enddate><creator>Sunada, Atsuko, MT</creator><creator>Kimura, Keigo, MT</creator><creator>Nishi, Isao, MT, PhD</creator><creator>Toyokawa, Masahiro, MT, PhD</creator><creator>Ueda, Akiko, MT</creator><creator>Sakata, Tomomi, MT</creator><creator>Suzuki, Takashi, MD, PhD</creator><creator>Inoue, Yoshitsugu, MD, PhD</creator><creator>Ohashi, Yuichi, MD, PhD</creator><creator>Asari, Seishi, MT, PhD</creator><creator>Iwatani, Yoshinori, MD, PhD</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-1005-9634</orcidid></search><sort><creationdate>20141001</creationdate><title>In Vitro Evaluations of Topical Agents to Treat Acanthamoeba Keratitis</title><author>Sunada, Atsuko, MT ; Kimura, Keigo, MT ; Nishi, Isao, MT, PhD ; Toyokawa, Masahiro, MT, PhD ; Ueda, Akiko, MT ; Sakata, Tomomi, MT ; Suzuki, Takashi, MD, PhD ; Inoue, Yoshitsugu, MD, PhD ; Ohashi, Yuichi, MD, PhD ; Asari, Seishi, MT, PhD ; Iwatani, Yoshinori, MD, PhD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c553t-d736133e4820dcd2c4b051ed54e765a50e80c336fb629a78731e72e3dfc61a0a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Acanthamoeba - drug effects</topic><topic>Acanthamoeba - genetics</topic><topic>Acanthamoeba - isolation &amp; purification</topic><topic>Acanthamoeba Keratitis - drug therapy</topic><topic>Acanthamoeba Keratitis - parasitology</topic><topic>Anti-Infective Agents, Local - pharmacology</topic><topic>Antiprotozoal Agents - pharmacology</topic><topic>Disinfectants - pharmacology</topic><topic>DNA, Protozoan - analysis</topic><topic>Genotype</topic><topic>Humans</topic><topic>Ophthalmic Solutions - pharmacology</topic><topic>Ophthalmology</topic><topic>RNA, Ribosomal, 18S - genetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sunada, Atsuko, MT</creatorcontrib><creatorcontrib>Kimura, Keigo, MT</creatorcontrib><creatorcontrib>Nishi, Isao, MT, PhD</creatorcontrib><creatorcontrib>Toyokawa, Masahiro, MT, PhD</creatorcontrib><creatorcontrib>Ueda, Akiko, MT</creatorcontrib><creatorcontrib>Sakata, Tomomi, MT</creatorcontrib><creatorcontrib>Suzuki, Takashi, MD, PhD</creatorcontrib><creatorcontrib>Inoue, Yoshitsugu, MD, PhD</creatorcontrib><creatorcontrib>Ohashi, Yuichi, MD, PhD</creatorcontrib><creatorcontrib>Asari, Seishi, MT, PhD</creatorcontrib><creatorcontrib>Iwatani, Yoshinori, MD, PhD</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Ophthalmology (Rochester, Minn.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sunada, Atsuko, MT</au><au>Kimura, Keigo, MT</au><au>Nishi, Isao, MT, PhD</au><au>Toyokawa, Masahiro, MT, PhD</au><au>Ueda, Akiko, MT</au><au>Sakata, Tomomi, MT</au><au>Suzuki, Takashi, MD, PhD</au><au>Inoue, Yoshitsugu, MD, PhD</au><au>Ohashi, Yuichi, MD, PhD</au><au>Asari, Seishi, MT, PhD</au><au>Iwatani, Yoshinori, MD, PhD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>In Vitro Evaluations of Topical Agents to Treat Acanthamoeba Keratitis</atitle><jtitle>Ophthalmology (Rochester, Minn.)</jtitle><addtitle>Ophthalmology</addtitle><date>2014-10-01</date><risdate>2014</risdate><volume>121</volume><issue>10</issue><spage>2059</spage><epage>2065</epage><pages>2059-2065</pages><issn>0161-6420</issn><eissn>1549-4713</eissn><abstract>Purpose To evaluate the effectiveness of topical agents for the treatment of Acanthamoeba keratitis (AK). Design Laboratory research. Participants Fifty-six Acanthamoeba isolates from 56 patients with clinically proven AK were studied. Methods The effectiveness of 7 agents against Acanthamoeba cysts was determined in vitro. The agents were 1.0% povidone-iodine, 0.05% benzalkonium chloride (BZC), 0.02% chlorhexidine gluconate (CHG), 0.1% propamidine isethionate, 0.02% polyhexamethylene biguanide (PHMB), 5.0% natamycin, and 1.0% voriconazole (VRCZ). These concentrations are those recommended for patients. In addition, 10-fold dilutions of each of the agents were tested. After exposing the cysts to each agent at 35°C for 1 hour or 24 hours, the agents were removed by centrifugal washing. The exposed cysts were observed by optical microscopy for 7 days. In addition, the fine structures of the exposed isolates were examined by transmission electron microscopy (TEM). The genotype of the isolates was determined by 18S rDNA fragment sequencing. Main Outcome Measures The in vitro susceptibility was determined by complete growth inhibition, and the morphologic appearance was determined by TEM. The genotypes of the 56 isolates were determined by 18S rDNA fragment sequencing. Results The Acanthamoeba cysts were most susceptible to natamycin, followed by povidone-iodine, BZC, PHMB, propamidine, and CHG. None of the strains was susceptible to VRCZ. The susceptibilities to PHMB and CHG may be time dependent and to propamidine may be concentration dependent. Transmission electron microscopy showed changes in the inner structure of the cysts exposed to natamycin and povidone-iodine. The Acanthamoeba genotype was T4 in 52 isolates, and cysts with the same genotype had different agent susceptibilities. Conclusions Natamycin and povidone-iodine had excellent cysti-static (or cystcidal) effects, and PHMB and propamidine did not. There was no correlation between agent effectiveness and Acanthamoeba genotype. Therefore, susceptibility tests of isolates are needed to choose the most appropriate agent, and our results can be a guideline for choosing the most appropriate agent for immediate empirical treatment of AK.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>24880905</pmid><doi>10.1016/j.ophtha.2014.04.013</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-1005-9634</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0161-6420
ispartof Ophthalmology (Rochester, Minn.), 2014-10, Vol.121 (10), p.2059-2065
issn 0161-6420
1549-4713
language eng
recordid cdi_proquest_miscellaneous_1566112505
source MEDLINE; Access via ScienceDirect (Elsevier)
subjects Acanthamoeba - drug effects
Acanthamoeba - genetics
Acanthamoeba - isolation & purification
Acanthamoeba Keratitis - drug therapy
Acanthamoeba Keratitis - parasitology
Anti-Infective Agents, Local - pharmacology
Antiprotozoal Agents - pharmacology
Disinfectants - pharmacology
DNA, Protozoan - analysis
Genotype
Humans
Ophthalmic Solutions - pharmacology
Ophthalmology
RNA, Ribosomal, 18S - genetics
title In Vitro Evaluations of Topical Agents to Treat Acanthamoeba Keratitis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-17T00%3A50%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=In%C2%A0Vitro%20Evaluations%20of%20Topical%20Agents%20to%20Treat%20Acanthamoeba%20Keratitis&rft.jtitle=Ophthalmology%20(Rochester,%20Minn.)&rft.au=Sunada,%20Atsuko,%20MT&rft.date=2014-10-01&rft.volume=121&rft.issue=10&rft.spage=2059&rft.epage=2065&rft.pages=2059-2065&rft.issn=0161-6420&rft.eissn=1549-4713&rft_id=info:doi/10.1016/j.ophtha.2014.04.013&rft_dat=%3Cproquest_cross%3E1566112505%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1566112505&rft_id=info:pmid/24880905&rft_els_id=1_s2_0_S0161642014003601&rfr_iscdi=true